219 related articles for article (PubMed ID: 30408788)
1. Effects of L-Carnitine on Mineral Metabolism in the Multicentre, Randomized, Double Blind, Placebo-Controlled CARNIDIAL Trial.
Mercadal L; Tezenas du Montcel S; Chonchol MB; Debure A; Depreneuf H; Servais A; Bassilios N; Assogba U; Allouache M; Prié D
Am J Nephrol; 2018; 48(5):349-356. PubMed ID: 30408788
[TBL] [Abstract][Full Text] [Related]
2. [Effect of Ronghuang Granule on serum FGF23, FGFRs and Klotho in non-dialysis patients with CKD-MBD and kidney deficiency and damp-heat syndrome].
Hu S; Wang D; Zhang R; Cao Y; Jin H; Mao Y; Wei L; Ren K; Zhang X; Wang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Dec; 38(12):1427-1432. PubMed ID: 30613009
[TBL] [Abstract][Full Text] [Related]
3. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
[TBL] [Abstract][Full Text] [Related]
4. Phosphate control in reducing FGF23 levels in hemodialysis patients.
Rodelo-Haad C; Rodríguez-Ortiz ME; Martin-Malo A; Pendon-Ruiz de Mier MV; Agüera ML; Muñoz-Castañeda JR; Soriano S; Caravaca F; Alvarez-Lara MA; Felsenfeld A; Aljama P; Rodriguez M
PLoS One; 2018; 13(8):e0201537. PubMed ID: 30086150
[TBL] [Abstract][Full Text] [Related]
5. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients.
Lin HH; Liou HH; Wu MS; Lin CY; Huang CC
Nephrology (Carlton); 2014 Nov; 19(11):672-8. PubMed ID: 25113414
[TBL] [Abstract][Full Text] [Related]
6. Relationship between cFGF23/Klotho ratio and phosphate levels in patients with chronic kidney disease.
Liu Z; Zhou H; Chen X; Chen H; Wang Y; Wang T; Cai L; Hong Y; Ke H; Zheng J
Int Urol Nephrol; 2019 Mar; 51(3):503-507. PubMed ID: 30689182
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Koizumi M; Komaba H; Fukagawa M
Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
[TBL] [Abstract][Full Text] [Related]
8. Association of klotho gene polymorphism and the regulation of calcium-phosphate metabolism disorders in patients with end-stage renal disease.
Zeng QY; Xia ZY; Tong YS; Sun L; Mou HB; Chen R; Bi GY; Liu CH
Nephrology (Carlton); 2019 Oct; 24(10):1001-1008. PubMed ID: 30537427
[TBL] [Abstract][Full Text] [Related]
9. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
Liabeuf S; Ryckelynck JP; El Esper N; Ureña P; Combe C; Dussol B; Fouque D; Vanhille P; Frimat L; Thervet E; Mentaverri R; Prié D; Choukroun G;
Clin J Am Soc Nephrol; 2017 Dec; 12(12):1930-1940. PubMed ID: 29074818
[TBL] [Abstract][Full Text] [Related]
10. FGF23 and the PTH response to paricalcitol in chronic kidney disease.
D'Arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
Eur J Clin Invest; 2020 Feb; 50(2):e13196. PubMed ID: 31863599
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD.
Malhotra R; Katz R; Hoofnagle A; Bostom A; Rifkin DE; Mcbride R; Probstfield J; Block G; Ix JH
Clin J Am Soc Nephrol; 2018 Jan; 13(1):36-44. PubMed ID: 29208626
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
Kuczera P; Adamczak M; Wiecek A
Clin Endocrinol (Oxf); 2014 Apr; 80(4):607-12. PubMed ID: 24111496
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.
Wan M; Smith C; Shah V; Gullet A; Wells D; Rees L; Shroff R
Nephrol Dial Transplant; 2013 Jan; 28(1):153-61. PubMed ID: 23180879
[TBL] [Abstract][Full Text] [Related]
14. Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients.
Pietrzyk B; Wyskida K; Ficek J; Kolonko A; Ficek R; Więcek A; Olszanecka-Glinianowicz M; Chudek J
Int Urol Nephrol; 2019 Mar; 51(3):519-526. PubMed ID: 30584645
[TBL] [Abstract][Full Text] [Related]
15. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects.
Martin KJ; Bell G; Pickthorn K; Huang S; Vick A; Hodsman P; Peacock M
Nephrol Dial Transplant; 2014 Feb; 29(2):385-92. PubMed ID: 24235081
[TBL] [Abstract][Full Text] [Related]
16. [Mineral metabolism in patients on chronic peritoneal dialysis].
Ceballos O ML; Rojo L A; Azócar P M; Ibacache M MJ; Delucchi B A; Quiroz Z L; Irarrázabal M C; Delgado B I; Ugarte P F; Cano Sch F
Rev Chil Pediatr; 2014 Feb; 85(1):31-9. PubMed ID: 25079181
[TBL] [Abstract][Full Text] [Related]
17. FGF23-Klotho Axis and Fractures in Patients Without and With Early CKD: A Case-Cohort Analysis of CARTaGENE.
Desbiens LC; Sidibé A; Ung RV; Mac-Way F
J Clin Endocrinol Metab; 2022 May; 107(6):e2502-e2512. PubMed ID: 35139204
[TBL] [Abstract][Full Text] [Related]
18. Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.
Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
BMC Nephrol; 2021 Nov; 22(1):374. PubMed ID: 34758731
[TBL] [Abstract][Full Text] [Related]
19. Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis-Effect on Fibroblast Growth Factor-23 Metabolism.
Fukao W; Hasuike Y; Yamakawa T; Toyoda K; Aichi M; Masachika S; Kantou M; Takahishi SI; Iwasaki T; Yahiro M; Nanami M; Nagasawa Y; Kuragano T; Nakanishi T
J Ren Nutr; 2018 Jul; 28(4):270-277. PubMed ID: 29703633
[TBL] [Abstract][Full Text] [Related]
20. Serum klotho: relation to fibroblast growth factor-23 and other regulators of phosphate metabolism in children with chronic kidney disease.
Sawires HK; Essam RM; Morgan MF; Mahmoud RA
Nephron; 2015; 129(4):293-9. PubMed ID: 25766835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
